Stock IRON DISC MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Disc Medicine, Inc.

Equities

IRON

US2546041011

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
28.53 USD +2.48% Intraday chart for Disc Medicine, Inc. +4.51% -50.61%
Apr. 08 Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating MT
Apr. 02 Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
GL
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
GL
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
GL
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
GL
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
GL
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
GL
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
AQ
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
GL
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
GL
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
AQ
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
GL
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
GL
Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Disc Medicine to Participate in Upcoming Investor Conferences
GL
Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates
AQ
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
AQ
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IRON Stock
  4. News Disc Medicine, Inc.
  5. Press Releases